Tag: Leukaemia
Search News
Scientists uncover promising leukaemia treatment targeting fat metabolism
17th October 2024
Researchers at Barts Cancer Institute reveal promising acute myeloid leukaemia treatment targeting fat metabolism, addressing the urgent need for better therapies.
Read more
Scientists uncover a promising strategy to combat leukaemia resistance
18th May 2023
Research reveals a vulnerability in leukaemia cells that causes them to fill with toxic fatty acids
Read more
Introducing Dr Özgen Deniz
21st December 2022
We are pleased to welcome Dr Özgen Deniz to Barts Cancer Institute (BCI) at Queen Mary University of London as a Lecturer and Group Leader. After receiving a Cancer Research UK Career Development Fellowship, Dr Deniz is establishing her own independent research group in BCI’s Centre for Haemato-Oncology.
Read more
BCI researcher part of Strategic Collaboration Agreement with Queen Mary, Envisagenics and Cancer Research Horizons
14th December 2022
BCI’s Dr Ana Rio-Machin is part of a new research collaboration agreement that will leverage Envisagenics’ SpliceCore® AI platform for expanded discovery and research in haematopoietic cancers.
Read more
Rewiring the biology of leukaemia cells to reverse drug resistance
20th April 2022
Researchers from Barts Cancer Institute at Queen Mary University of London have identified a way to reverse resistance to a group of cancer drugs, known as kinase inhibitors, in leukaemia cells. By rewiring the inner workings of the cancer cells, the team was able to prime leukaemia cells for sensitivity to treatment in the laboratory.
Read more
Barts Cancer Institute at ASH 2021
17th December 2021
In December each year, the American Society of Hematology (ASH) hosts its Annual Meeting and Exposition – the premier event in malignant and non-malignant haematology. The event represents an invaluable opportunity for researchers at Barts Cancer Institute, Queen Mary University of London to highlight their blood cancer research on an international stage.
Read more